MAPT and Alzheimer disease: Tau biomarkers are also increasingly being implemented in clinical practice and show promise for both diagnostic and prognostic purposes, as tau biomarkers demonstrate a higher specificity for AD and are more closely associated with cognitive decline and disease progression.2, 3, 4, 5, 6, 7, 8, 9